We recently took on the JPMorganChase Corporate Challenge! Employees from across the business enjoyed the opportunity to celebrate teamwork while also focusing on their wellness. We are already looking forward to next year! #JPMCC #WhyWeExel
Über uns
Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat. After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/2XXw9w3 For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
- Website
-
http://www.exelixis.com
External link for Exelixis
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 1.001-5.000 Mitarbeiter
- Hauptsitz
- Alameda, California
- Typ
- Öffentliches Unternehmen
- Gegründet
- 1994
Standorte
-
Primäre
Wegbeschreibung erhalten
1851 Harbor Bay Pkwy
Alameda, California 94502, US
-
Wegbeschreibung erhalten
640 Freedom Business Center Dr
King of Prussia, Pennsylvania 19406, US
Employees at Exelixis
Aktualisierungen
-
This month, we hosted our annual summer picnic to thank our team for their continued hard work and dedication. Their enthusiastic engagement and creativity allows us to keep pushing toward better cancer care for patients. #WhyWeExel
-
We encourage an environment where diversity flourishes and women are empowered. Hear stories from our team about the impact of female mentorship and the inspiration they draw from their colleagues. #WomensEqualityDay
-
NEWS: We are excited to announce the U.S. Food and Drug Administration (FDA) accepted our supplemental New Drug Application (sNDA) for our flagship product for the treatment of advanced neuroendocrine tumors (NET). Read on for additional information: https://bit.ly/3WSqQ0I.
-
Our Exelixis volunteers continue to support our local community! Check out highlights from recent volunteer events: ◾️Built 250 backpacks for disadvantaged students in the East Bay for Safe Passages through Life Science Cares Bay Area ◾️Volunteered with animals at Friends of the Alameda Animal Shelter (FAAS)
-
We recently had the honor of hosting patient advocates Laura Esfeller and Katie Coleman, who shared insights with our employees on how peer-to-peer support and advocacy have positively impacted their cancer journeys. This powerful discussion reinforced our ongoing commitment to building partnerships with advocacy organizations that share our dedication to improving cancer care. Through our charitable contribution program, we support these organizations to ensure cancer patients and survivors like Laura and Katie have access to essential resources. Together, we can make a meaningful difference in the lives of those affected by cancer.
Ähnliche Seiten
Jobs durchsuchen
Aktie
EXEL
NASDAQ
20 Minuten Verzögerung
$25.82
0.09 (0.35%)
- Öffnen Sie
- 25.75
- Niedrig
- 25.56
- Hoch
- 25.845
Daten von Refinitiv
Siehe mehr Informationen aufFinanzierung
Exelixis
5 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 135.0M